These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
525 related articles for article (PubMed ID: 16682955)
1. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955 [TBL] [Abstract][Full Text] [Related]
2. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways. Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Kurokawa H; Arteaga CL Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237 [TBL] [Abstract][Full Text] [Related]
4. EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2. Wu Y; Chen Z; Ullrich A Biol Chem; 2003 Aug; 384(8):1215-26. PubMed ID: 12974390 [TBL] [Abstract][Full Text] [Related]
5. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors. Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676 [TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of FGF-induced MAPK activation by the receptor-like protein tyrosine phosphatase LAR. Wang X; Weng LP; Yu Q Oncogene; 2000 May; 19(19):2346-53. PubMed ID: 10822386 [TBL] [Abstract][Full Text] [Related]
7. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor. Easton JB; Royer AR; Middlemas DS J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649 [TBL] [Abstract][Full Text] [Related]
8. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. Pan MH; Lin CC; Lin JK; Chen WJ J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658 [TBL] [Abstract][Full Text] [Related]
9. Complex regulation of the fibroblast growth factor-binding protein in MDA- MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. Kagan BL; Henke RT; Cabal-Manzano R; Stoica GE; Nguyen Q; Wellstein A; Riegel AT Cancer Res; 2003 Apr; 63(7):1696-705. PubMed ID: 12670924 [TBL] [Abstract][Full Text] [Related]
10. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells. Johnson MR; Valentine C; Basilico C; Mansukhani A Oncogene; 1998 May; 16(20):2647-56. PubMed ID: 9632141 [TBL] [Abstract][Full Text] [Related]
11. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652 [TBL] [Abstract][Full Text] [Related]
12. FGF receptor phosphotyrosine 766 is a target for Grb14 to inhibit MDA-MB-231 human breast cancer cell signaling. Cailliau K; Perdereau D; Lescuyer A; Chen H; Garbay C; Vilain JP; Burnol AF; Browaeys-Poly E Anticancer Res; 2005; 25(6B):3877-82. PubMed ID: 16309174 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells. Capiati DA; Rossi AM; Picotto G; Benassati S; Boland RL J Cell Biochem; 2004 Oct; 93(2):384-97. PubMed ID: 15368364 [TBL] [Abstract][Full Text] [Related]
14. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418 [TBL] [Abstract][Full Text] [Related]
15. Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase. Mochizuki Y; Tsuda S; Kanetake H; Kanda S Oncogene; 2002 Oct; 21(46):7027-33. PubMed ID: 12370824 [TBL] [Abstract][Full Text] [Related]
17. ET-18-OCH3 inhibits the phosphorylation and activation of p70 S6 kinase in MCF-7 cells. Arthur G; Samadder P; Bittman R Anticancer Res; 2005; 25(1A):95-100. PubMed ID: 15816524 [TBL] [Abstract][Full Text] [Related]
18. Docking protein SNT1 is a critical mediator of fibroblast growth factor signaling during Xenopus embryonic development. Akagi K; Kyun Park E; Mood K; Daar IO Dev Dyn; 2002 Mar; 223(2):216-28. PubMed ID: 11836786 [TBL] [Abstract][Full Text] [Related]
19. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Ong SH; Hadari YR; Gotoh N; Guy GR; Schlessinger J; Lax I Proc Natl Acad Sci U S A; 2001 May; 98(11):6074-9. PubMed ID: 11353842 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation. Wieder R; Fenig E; Wang H; Wang Q; Paglin S; Menzel T; Gabrilove J; Fuks Z; Yahalom J J Cell Physiol; 1998 Dec; 177(3):411-25. PubMed ID: 9808150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]